-
Business
-
Policy & Business
-
-
Federal IT
-
Information Technology
-
-
State & Local
-
State & Local Government
-
-
Defense
-
Defense & Intelligence
-
-
Healthcare
-
Healthcare Policy & IT
-
-
Energy
-
Energy Policy & Technology
-
-
Education
-
Education Policy & Technology
-
U.S. pauses Eli Lilly's trial of a coronavirus antibody treatment over safety concerns
CNBC: Eli Lilly’s late-stage trial of its leading monoclonal antibody treatment for the coronavirus has been paused by U.S. health regulators over potential safety concerns, the company confirmed to CNBC on Tuesday.
“Safety is of the utmost importance to Lilly. We are aware that, out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment,” spokeswoman Molly McCully told CNBC. “Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety of the patients participating in this study.”
Share
Top Stories
- VA Says Its Renewed Infrastructure Review Will Focus on Building First
- Veterans Affairs Unveils Draft for $60B T4NG 2 Vehicle
- VA is Working to Add New Features to its Health and Benefits App
- Homelessness Among Veterans Has Been Cut in Half since 2010, VA Says
- Leidos partners with Accenture to deliver CDC cloud modernization
- Top 10 privacy and cybersecurity stories of 2022
- How to Solve the Healthcare Data Conundrum
- Top 10 privacy and cybersecurity stories of 2022
- Cardinal Health CIO Michelle Greene on simplifying transformation
- Get a handle on insider threats with industry intel
- Defense Department Health Plan Cuts Its Pharmacy Network by Nearly 15,000 Outlets
- Senator questions Mark Zuckerberg over Meta's healthcare data collection policies
- ‘I Can Go Anywhere’: How Service Dogs Help Veterans With PTSD
- Cutting Thousands of Medical Personnel Won’t Reduce Access to Care, Army Surgeon General Says
- VA ‘Moving Toward Full Compliance’ With Geospatial Data Law, Watchdog Finds
- NIH Injects $130M to Provide Quality Tools, Data for AI in Medicine
Whitepapers & Special Reports
i360Gov Newsletters
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe NowTrending
- Leidos partners with Accenture to deliver CDC cloud modernization
- Cardinal Health CIO Michelle Greene on simplifying transformation
- Army’s New Plan to ‘Transform’ Soldier Health Care with Technology
- VA Systems are Vulnerable to Cyber Intrusions Due to Lack of Effective Oversight, Report Says
- The business value of NLP: 5 success stories
- Defense Department Health Plan Cuts Its Pharmacy Network by Nearly 15,000 Outlets
- VA ‘Moving Toward Full Compliance’ With Geospatial Data Law, Watchdog Finds
- NIH Injects $130M to Provide Quality Tools, Data for AI in Medicine
Also in Healthcare Policy & IT
About
i360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Contact Us
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
Newsletters
Copyright © 2009-2024 i360Communications, LLC.